Xponance Inc. Makes New $229,000 Investment in SpringWorks Therapeutics (NASDAQ:SWTX)

Xponance Inc. bought a new position in shares of SpringWorks Therapeutics (NASDAQ:SWTX) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,185 shares of the company’s stock, valued at approximately $229,000.

A number of other institutional investors have also recently added to or reduced their stakes in SWTX. Huntington National Bank lifted its position in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after acquiring an additional 192 shares during the period. AlphaQuest LLC lifted its position in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after acquiring an additional 414 shares during the period. State of Wyoming lifted its position in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after acquiring an additional 433 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at $56,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of SpringWorks Therapeutics during the 1st quarter valued at $208,000.

SpringWorks Therapeutics Stock Performance

NASDAQ SWTX opened at $46.99 on Friday. The company has a market capitalization of $3.54 billion, a P/E ratio of -13.78 and a beta of 0.68. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $62.00. The stock has a 50 day moving average price of $46.74 and a 200-day moving average price of $45.24.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 115.60% and a negative return on equity of 51.10%. The company had revenue of $49.09 million for the quarter, compared to analysts’ expectations of $64.19 million. As a group, equities analysts predict that SpringWorks Therapeutics will post -2.05 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SWTX. HC Wainwright reiterated a “neutral” rating and issued a $47.00 target price (down previously from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Wedbush restated a “neutral” rating and set a $47.00 price objective (down previously from $81.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. TD Cowen restated a “hold” rating and set a $47.00 price objective (down previously from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Barclays restated an “equal weight” rating and set a $47.00 price objective (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Finally, Guggenheim restated a “neutral” rating and set a $47.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, May 12th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $52.57.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.